Biocon Limited has announced a significant leadership transition effective April 1, 2026, as part of the full integration of Biocon Biologics as a wholly-owned subsidiary. Long-time veteran Shreehas Tambe takes over as the first CEO and Managing Director of the unified company, while Kedar Upadhye steps in as the new Chief Financial Officer. This move aims to create a streamlined structure to boost global competitiveness in biosimilars, generics, and specialty areas like diabetes and oncology.
Glimpse:
On March 27, 2026, Biocon Limited revealed that Shreehas Tambe, previously heading Biocon Biologics, will assume the role of CEO and Managing Director from April 1, 2026, for a five-year term (subject to shareholder approval). Kedar Upadhye, formerly CFO of Biocon Biologics, has been appointed as CFO of Biocon Limited. Outgoing CEO Siddharth Mittal, who joined in 2013, will move to another leadership position within the group. The changes align with the company’s strategy to build a unified, scaled biopharma platform.
Biocon Limited, a leading Indian biopharmaceutical company, has initiated a key leadership reshuffle to support its ongoing business integration. Effective April 1, 2026, Shreehas Tambe will take charge as Chief Executive Officer and Managing Director of Biocon Limited. This marks the first time a single leader will helm the combined entity following the complete integration of Biocon Biologics Limited as a wholly-owned subsidiary. The restructuring is designed to simplify operations and strengthen the company’s position to compete more effectively on the global stage.
Tambe brings nearly three decades of experience with Biocon, having started as a management trainee. He has played a pivotal role in growing several businesses, including leading the global expansion of the insulins segment and establishing Asia’s largest integrated insulins manufacturing facility in Malaysia. Most recently, as CEO and Managing Director of Biocon Biologics, he guided the company to become one of the world’s top five biosimilar players by revenue, achieving a valuation of USD 5.5 billion in 2025. He also successfully oversaw the acquisition and integration of Viatris’ biosimilars business, creating a fully integrated biologics platform. Tambe holds 61 patents from his early work in research and development.
In parallel, Kedar Upadhye has been named Chief Financial Officer of Biocon Limited, effective the same date. This appointment comes alongside the transition of previous CEO and Managing Director Siddharth Mittal, who joined the company in 2013 and contributed significantly first as CFO and later in the top leadership role. Mittal will now shift to a different leadership position within the broader Biocon Group. The unified structure will focus on advancing a strong portfolio covering biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, targeting critical therapeutic areas such as diabetes, obesity, oncology, and immunology.
The changes reflect Biocon’s vision to anticipate patient needs and build scale ahead of market demands. With a simplified corporate framework, the company aims to accelerate sustainable growth, expand its global footprint, and deliver more affordable healthcare solutions worldwide through innovation and operational excellence.
“Biocon has consistently grown by anticipating patient needs and building ahead of the curve. With the integration of our generics and biosimilars businesses, we are creating a uniquely positioned, globally scaled biopharma enterprise. Shreehas has been at the forefront of this transformation… Under his leadership, Biocon Biologics has emerged as one of the world’s top five biosimilar companies, with a valuation of USD 5.5 billion. I am confident he will drive disciplined execution and translate our scale into sustained global leadership.”
By
HB Team
Related News
